Fused Mescaline Derivatives for Lower-Toxicity Psychiatric Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mescaline, a psychoactive compound with therapeutic potential, is associated with adverse side effects such as panic attacks, paranoia, and nausea, necessitating the development of improved derivatives with reduced toxicity and improved therapeutic profiles.
Innovation Solution
Development of fused heterocyclic mescaline derivatives with a substituted ethylamine chain, featuring specific chemical structures that modulate receptors and transport proteins to mitigate adverse effects and enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mescaline is used as a psychoactive compound, then therapeutic potential and spiritual benefits are achieved, but adverse side effects such as panic attacks, paranoia, and nausea occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of mescaline through substitution at specific positions (C1, C2, C3, C4, C5, C6 of the phenyl ring and positions on the ethylamine chain) with various functional groups including heterocyclic rings, alkyl groups, halogens, and hydroxyl groups. These structural parameter changes produce derivatives with reduced adverse effects while maintaining or enhancing therapeutic potential, directly resolving the contradiction between therapeutic benefit and harmful side effects
2Object-affected harmful factors
If the chemical structure of mescaline is modified to reduce toxicity, then adverse side effects are reduced, but the psychoactive and therapeutic efficacy may be compromised
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific positions of the mescaline molecule rather than uniform changes throughout the structure. Different substitutions are made at different positions (phenyl ring positions C1-C6, ethylamine chain positions) with specific functional groups selected for each position to optimize the balance between reduced toxicity and maintained therapeutic efficacy. This localized approach allows preservation of essential psychoactive properties while eliminating harmful effects
Data Source
AI summary
Disclosed are novel fused mescaline derivative compounds, notably substituted ethylamine fused heterocyclic mescaline derivatives, including substituted ethylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.